Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of IL-11 in DDAVP Unresponsive

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females \>= 18 years of age.~* A diagnosis of hemophilia A, moderate (FVIII:C 0.01-0.04 U/ml) or mild (FVIII:C \>= 0.05 U/ml); or a diagnosis of VWD, defined by a low VWF:RCo and past bleeding history.~* For those with VWD, an inability to use DDAVP due to i) unresponsiveness defined as VWF:RCo or FVIII:C level lower than 50 IU/dl or less than a 3-fold increase after 0.3 microgram/kg DDAVP; ii) allergic reactions or seizures; or iii) a contraindication to DDAVP.~* Willingness to have blood drawn.~* Willingness to sign informed consent.~Exclusion Criteria:~* Presence of other bleeding disorders, acquired Von Willebrand disease, primary thrombocytopenia.~* Use of immunomodulatory or experimental drugs, or diuretics.~* Pregnant or lactating women.~* Previous cardiac disease, congestive failure, arrhythmia (e.g. atrial fibrillation, atrial flutter), hypertension, MI, stroke, or thrombosis.~* Past allergic reaction to Neumega.~* Surgery within the past 8 weeks.~* Inability to comply with study protocol requirements.~* Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin or NSAIDs.~* Treatment with DDAVP, cryoprecipitate, whole blood, plasma and plasma derivatives containing substantial quantities of FVIII and/or VWF within five days of study.~* Baseline safety and/or hematology lab values outside the normal limits and/or an EKG indicating an arrhythmia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neumega (Oprelveken, Interleukin 11) (Type: EXPERIMENTAL): Neumega (Oprelveken, interleukin-11 (IL-11) 25 microgram/kilogram by subcutaneou injection once daily for four days, followed on day 4 DDAVP 0.3 microgram/kilogram intravenously 30 minutes after neumega

Based on this trial design, predict the completion outcome and termination type (if applicable).